Trial Profile
EVALUATION OF THE SAFETY AND EFFICACY OF TREATMENT WITH SINGLE DOSES OF CHF 4226 pMDI IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE A Multicenter, Randomized, Double-Blind,Placebo-Controlled, 5-Way Crossover Study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Carmoterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Chiesi Farmaceutici
- 10 Mar 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 10 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Feb 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.